Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed)

0
372

Funding Opportunity ID: 321057
Opportunity Number: RFA-DK-19-505
Opportunity Title: Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
CFDA Number(s): 93.847
Eligible Applicants: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see the funding announcement for eligibility details
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Sep 27, 2019
Close Date: Dec 03, 2019
Last Updated Date: Sep 27, 2019
Award Ceiling: $3,000,000
Award Floor: $0
Estimated Total Program Funding:
Expected Number of Awards:
Description: This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time FOA to provide funds to the AMP T2D KP to continue the development of the web portal and underlying, curated knowledge base; as well as to become the flagship resource encompassing the myriad types of data and information that provides an understanding of the biological heterogeneity in patients with T2D and its complications. In its next five-year period, the AMP T2D KP will be expected to expand the KPs data sets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base. To support the conduct of these studies, the AMP T2D KP will coordinate, support, and work with companion Functional Genomic Project awardees (RFA-DK-19-012) to form a Consortium. The AMP T2D KP will also oversee an opportunity pool of funds to solicit collaborative projects to accomplish the objectives of the Consortium.
Version: 1





Visit the Official Webpage For More Details on Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed)